328 results on '"Raboisson, Pierre"'
Search Results
2. Blocking NS3–NS4B interaction inhibits dengue virus in non-human primates
3. Discovery of gem-Dimethyl-hydroxymethylpyridine Derivatives as Potent Non-nucleoside RSV Polymerase Inhibitors.
4. A pan-serotype dengue virus inhibitor targeting the NS3–NS4B interaction
5. Discovery of JNJ-1802, a First-in-Class Pan-Serotype Dengue Virus NS4B Inhibitor
6. Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of MASH
7. Novel non-HAP class A HBV capsid assembly modulators have distinct in vitro and in vivo profiles
8. Publisher Correction: A pan-serotype dengue virus inhibitor targeting the NS3–NS4B interaction
9. An in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polymer treatment outcomes in chronic hepatitis B patients
10. Class A capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation.
11. The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir
12. Discovery of Acyl-Indole Derivatives as Pan-Serotype Dengue Virus NS4B Inhibitors.
13. From Oxetane to Thietane: Extending the Antiviral Spectrum of 2′-Spirocyclic Uridines by Substituting Oxygen with Sulfur
14. Synthesis and evaluation of novel HCV replication inhibitors
15. Discovery of oral PDL1 small molecule inhibitors specifically designed for the treatment of chronic hepatitis B
16. Characterization of a dengue NS4B inhibitor originating from an HCV small molecule library
17. The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitorin vitroand confer resistance to nirmatrelvir
18. Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor
19. List of Contributors
20. Macrocycles
21. ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model
22. Cyclic nucleotide phosphodiesterase type 4 inhibitors: Evaluation of pyrazolo[1,5- a]-1,3,5-triazine ring system as an adenine bioisostere
23. Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development
24. ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibitsin vivoefficacy in a Syrian Hamster model
25. FRI-272 - An in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polymer treatment outcomes in chronic hepatitis B patients
26. Identification of novel short chain 4-substituted indoles as potent α vβ 3 antagonist using structure-based drug design
27. Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH)
28. Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry
29. Discovery and Development of the HCV Protease Inhibitor TMC435
30. Novel potent and selective α vβ 3/α vβ 5 integrin dual antagonists with reduced binding affinity for human serum albumin
31. A general approach toward the synthesis of C-nucleoside pyrazolo[1,5-a]-1,3,5-triazines and their 3',5'-bisphosphate C-nucleotide analogues as the first reported in vitro stable P2Y (sub)1 -receptor antagonists
32. Abstract 1758: Discovery of novel potent and selective inhibitors of PRMT5 with anti-tumor activity in hepatocellular carcinoma and lung pre-clinical models
33. ALG-000184, a prodrug of capsid assembly modulator ALG-001075, demonstrates best-in-class preclinical characteristics for the treatment of chronic hepatitis B
34. Molecular, cellular, and pharmacological characterization of beta-selective partial agonists of human thyroid hormone receptor for the treatment of non-alcoholic steatohepatitis
35. Discovery of 3-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one (JNJ-53718678), a Potent and Orally Bioavailable Fusion Inhibitor of Respiratory Syncytial Virus
36. Antiviral Properties and Mechanism of Action Studies of the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379
37. Design, Synthesis, and Biological Evaluation of Novel Indoles Targeting the Influenza PB2 Cap Binding Region
38. Design and synthesis of tetrahydropyridopyrimidine based Toll-Like Receptor (TLR) 7/8 dual agonists
39. Discovery of selective 2,4-diaminoquinazoline toll-like receptor 7 (TLR 7) agonists
40. Design, synthesis and structure–activity relationships of a series of 9-substituted adenine derivatives as selective phosphodiesterase type-4 inhibitors
41. Practical Synthesis of Ethyl 3-Fluoro-1-pyrrole-2-carboxylate: A Key Fragment of a Potent Drug Candidate against Hepatitis B Virus
42. A small-molecule fusion inhibitor of influenza virus is orally active in mice
43. Inhibition of platelet function by administration of MRS2179, a P2Y 1 receptor antagonist
44. Discovery of 3‑({5-Chloro-1-[3-(methylsulfonyl)propyl]‑1H‑indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro‑2H‑imidazo[4,5‑c]-pyridin-2-one (JNJ-53718678), a Potent and Orally Bioavailable Fusion Inhibitor of...
45. 2,4-Diaminoquinazolines as Dual Toll-like Receptor (TLR) 7/8 Modulators for the Treatment of Hepatitis B Virus
46. Synthesis and Evaluation of N-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV)
47. Chapter 10 - Macrocycles: Under-Explored and Poorly Exploited Drug Class Despite the Proven Therapeutic Potential
48. Identification and Optimization of Pyrrolo[3,2-d]pyrimidine Toll-like Receptor 7 (TLR7) Selective Agonists for the Treatment of Hepatitis B
49. Practical Synthesis of Ethyl 3-Fluoro-1-pyrrole-2-carboxylate: A Key Fragment of a Potent Drug Candidate against Hepatitis B Virus
50. Novel Pyrimidine Toll-like Receptor 7 and 8 Dual Agonists to Treat Hepatitis B Virus
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.